Piper Jaffray Remains Bullish on Horizon Pharma (HZNP) Despite Sell-Off; Says Business is Sustainable
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Horizon Pharma plc Recognizes Rare Disease Community on the "Rarest Day of the Year"
February 29, 2016 7:30 AM ESTDUBLIN, IRELAND -- (Marketwired) -- 02/29/16 -- Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today joins rare disease patient advocates worldwide in supporting the ninth annual international Rare Disease Day.
Organized annually on the last day of February by the European Organization for Rare Diseases (EURORDIS) and supported in the United... More
Horizon Pharma plc Announces Record Fourth-Quarter and Full-Year 2015 Financial Results and Confirms Full-Year 2016 Sales and Adjusted EBITDA Guidance
February 29, 2016 7:00 AM ESTDUBLIN, IRELAND -- (Marketwired) -- 02/29/16 -- Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced its fourth-quarter and full-year 2015 financial results today and confirmed its full-year 2016 net sales and adjusted EBITDA guidance.
Financial Highlights (in millions except for per share amounts and % % percentages) Q4 15 Q4 14 Change FY 15 FY 14 Change ------- ------- ------ ------- ------- ------ Net sales $ 244.5 $ 103.8 135 $ 757.0 $ 297.0 155 Net income (loss) 24.0 (31.6) NM 39.5 (263.6) NM Adjusted non-GAAP net income 102.4 25.9 295 305.9 72.1 324 Adjusted EBITDA 122.5 34.8 252 362.1 87.1 316 Earnings (loss) per share - basic $ 0.15 $ (0.27) NM... More
